New 'Four-in-One' antibody takes on Hard-to-Treat blood cancers
NCT ID NCT05104775
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial is testing a new drug called GNC-035, a special antibody that targets four different signals on cancer cells. It is being given to 33 adults with blood cancers like lymphoma or leukemia that have come back or not responded to other treatments. The main goals are to check the drug's safety, find the best dose, and see if it shows any signs of shrinking tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
GNC-035 (a tetra-specific antibody given by IV infusion)
What this could lead to
If it works, this could point toward a new treatment option for people with blood cancers that have stopped responding to standard therapies.
What could go wrong
This is a very early Phase 1 trial with only 33 participants, so it is primarily testing safety and dosing—not yet proving effectiveness. The drug may cause side effects or fail to shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOLOGIC MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Affiliated Hospital of Guizhou Medical University
Guiyang, Guizhou, China
-
Guangzhou First People's Hospital
Guangzhou, Guangdong, China
-
Ruijin Hospital, Shanghai Jiaotong University School of Medicine
Shanghai, Shanghai Municipality, 200025, China
-
Shengjing Hospital of China Medical University
Shenyang, Liaoning, China
-
The Fourth Hospital of Hebei Medical University
Shijiazhuang, Hebei, China
-
The Second People's Hospital of Yibin
Yibin, Sichuang, China
-
Union Hospital Tongji Medical College Huazhong University of Science and Technology
Wuhan, Hubei, China